ArticleAnnals of hematology2026
First clinical and molecular characterization of two rare complex β-globin variants in Chinese population using third generation sequencing.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWith the widespread application of third-generation sequencing (TGS) technology, an increasing number of rare or previously unreported β-globin gene variants have been discovered. This study aims to characterize two rare complex β-globin gene variants identified in the Chinese population using TGS, aiming to enrich the spectrum of globin gene variations in this ethnic group.
methodsTwo unrelated Chinese families residing in Fujian Province were recruited for this study. Hematological screening was conducted via routine blood tests and capillary hemoglobin (Hb) electrophoresis. To detect both common and rare globin gene variants, a combination of conventional thalassemia gene detection, TGS, gap-PCR, and Sanger sequencing was employed.
resultsHematological screening of the proband from Family 1 revealed a decreased Hb level (102 g/L), elevated Hb A2 (9.3%), and an abnormal Hb band in zone 10. TGS identified a rare αααanti4.2 variant co-existing with Hb Stockholm [β7(A4)Glu > Asp; HBB:c.24G > T] in this proband. Pedigree analysis showed that the proband’s 6-month-old daughter inherited the αααanti4.2 variant (presenting with reduced MCV and MCH) but without Hb variant. The 29-year-old female proband from Family 2 exhibited remarkably reductions in MCV, MCH, and Hb A2, along with an abnormal Hb band in zone 12. Conventional testing detected the common –SEA deletion, while TGS further identified an additional rare Hb Pyrgos [β83(EF7)Gly > Asp; HBB:c.251G > A] variant combined with a rare IVS-II-180(T > C) (HBB:c.315 + 180 T > C) variant in the proband.
conclusionThis study is the first to describe these two rare complex Hb variants in the Chinese population. Our findings expand the knowledge of rare Hb variants and further strengthen the clinical utility of TGS in thalassemia gene testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.